Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | ATP4A | P20648 | 2/20 | 0.38 |
| ▸ | ATP4B | P51164 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1271836 | 0.86 | NR1H2 (0.50) | NR1H2NR1H3ESR1ESR2FGFR1 | |
| SCHEMBL1271037 | 0.83 | NR1H2 (0.58) | NR1H2NR1H3ESR1FGFR1GRIN2B | |
| SCHEMBL1272198 | 0.82 | NR1H2 (0.49) | NR1H2NR1H3FGFR1ALDH1A1HPGD | |
| SCHEMBL1271065 | 0.78 | NR1H2 (0.46) | NR1H2NR1H3ESR1FGFR1ALDH1A1 | |
| SCHEMBL6457343 | 0.76 | ESR1 (0.41) | ESR1ESR2CYP17A1FGFR1LMNA | |
| SCHEMBL1271032 | 0.74 | NR1H2 (0.67) | NR1H2NR1H3 | |
| SCHEMBL1272775 | 0.73 | NR1H2 (0.77) | NR1H2NR1H3 | |
| SCHEMBL1272307 | 0.71 | NR1H2 (0.78) | NR1H2NR1H3 | |
| SCHEMBL1272765 | 0.71 | NR1H2 (0.56) | NR1H2NR1H3FGFR1ALDH1A1LMNA | |
| SCHEMBL1272293 | 0.71 | NR1H2 (0.64) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | NR1H2 2/4885NR1H3 3/4885ESR1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.